Parasympathetic neurons in the cranial medial ventricular fat pad on the dog heart selectively decrease ventricular contractility.
We hypothesized that selective control of ventricular contractility might be mediated by postganglionic parasympathetic neurons in the cranial medial ventricular (CMV) ganglion plexus located in a fat pad at the base of the aorta. Sinus rate, atrioventricular (AV) conduction (ventricular rate during atrial pacing), and left ventricular contractile force (LV dP/dt during right ventricular pacing) were measured in eight chloralose-anesthetized dogs both before and during bilateral cervical vagus stimulation (20-30 V, 0.5 ms pulses, 15-20 Hz). Seven of these dogs were tested under beta-adrenergic blockade (propranolol, 0.8 mg kg(-1) i.v.). Control responses included sinus node bradycardia or arrest during spontaneous rhythm, high grade AV block or complete heart block, and a 30% decrease in contractility from 2118 +/- 186 to 1526 +/- 187 mm Hg s(-1) (P < 0.05). Next, the ganglionic blocker trimethaphan (0.3-1.0 ml of a 50 microg ml(-1) solution) was injected into the CMV fat pad. Then vagal stimulation was repeated, which now produced a relatively small 5% (N.S., P > 0.05) decrease in contractility but still elicited the same degree of sinus bradycardia and AV block (N = 8, P < 0.05). Five dogs were re-tested 3 h after trimethaphan fat pad injection, at which time blockade of vagally-induced negative inotropy was partially reversed, as vagal stimulation decreased LV dP/dt by 19%. The same dose of trimethaphan given either locally into other fat pads (PVFP or IVC-ILA) or systemically (i.v.) had no effect on vagally-induced negative inotropy. Thus, parasympathetic ganglia located in the CMV fat pad mediated a decrease in ventricular contractility during vagal stimulation. Blockade of the CMV fat pad had no effect on vagally-mediated slowing of sinus rate or AV conduction.
Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20007, USA.
L W
LW
Dickerson
D J
DJ
Rodak
T J
TJ
Fleming
P J
PJ
Gatti
V J
VJ
Massari
J C
JC
McKenzie
R A
RA
Gillis
D000273:Adipose Tissue / Q000187:drug effects / Q000294:innervation / Q000502:physiology; D000818:Animals; D001283:Atrioventricular Node / Q000187:drug effects / Q000294:innervation / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D004285:Dogs; D004558:Electric Stimulation; D004562:Electrocardiography; D005726:Ganglia, Parasympathetic / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D006321:Heart / Q000187:drug effects / Q000294:innervation*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006352:Heart Ventricles / Q000187:drug effects / Q000294:innervation; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D012849:Sinoatrial Node / Q000187:drug effects / Q000294:innervation / Q000502:physiology; D014294:Trimethaphan / Q000008:administration & dosage / Q000494:pharmacology; D014630:Vagus Nerve / Q000187:drug effects / Q000502:physiology; D016276:Ventricular Function
D018680:Cholinergic Antagonists; D014294:Trimethaphan